2013-08-05, Source: AllaChem, LLC
AllaChem, LLC announces the beginning of Phase I clinical studies of AV4025, a potent small molecule for the treatment of chronic hepatitis C infection. Hallandale Beach, Fl - July 25, 2013 - Alla Chem, LLC announced today the initiation of phase I clinical studies with AV4025, a next in-class small molecule HCV NS5A Inhibitor for the treatment of chronic hepatitis C infection. A double-blind, placebo-controlled, single ascending dose (10, 20 and 40 mg) study will evaluate safety, tolerability and pharmacokinetics of AV4025 upon oral administration in 30 healthy volunteers. The results of the pre-clinical and clinical studies will be presented at the 10th International Conference "Viral Hepatitis: Epidemiology, Diagnostics, Treatment and Prevention", September 17-19, 2013, Moscow, Russian Federation.
Alena Ivachtchenko, MBA
Director Business Development